Luo, J., Sarpatwari, A., and Kesselheim, A.S., “Regulatory Solutions to the Problem of High Generic Drug Costs,” Open Forum Infectious. Diseases 2, no. 4 (2015): ofv179.CrossRefGoogle Scholar

Carrier, M.A., Levidow, N., and Kesselheim, A.S., “Using Antitrust Law to Challenge Turing’s Daraprim Price Increase,” Berkeley Technology Law Journal 31 (2016): 1379–1408.Google Scholar

Thomas, K., “Patients Eagerly Awaited a Generic Drug. Then They Saw theP-price,” New York Times, February 23, 2018, available at <https://www.nytimes.com/2018/02/23/health/valeant-drug-price-syprine.html> (last visited October 24, 2020).+(last+visited+October+24,+2020).>Google Scholar

Maynard, J. and Furia-Helms, A., “FDA is Working to Bridge Gaps and Meet Needs for Rare Disease Product Development,” U.S. Food and Drug Administration, available at <https://www.fda.gov/news-events/fda-voices-perspectives-fda-leadership-and-experts/fda-working-bridge-gaps-and-meet-needs-rare-disease-product-development> (last visited October 24, 2020).+(last+visited+October+24,+2020).>Google Scholar

Sarpatwari, A., Beall, R.F., Abdurrob, A., He, M., and Kesselheim, A.S., “Evaluating the Impact of the Orphan Drug Act’s Seven-Year Market Exclusivity Period,” Health Affairs 37 no. 5 (2018): 732–737.CrossRefGoogle Scholar

Sarpatwari, A. and Kesselheim, A.S., “Reforming the Orphan Drug Act for the 21st Century,” New England Journal of Medicine 381, no. 2 (2019): 106–109.CrossRefGoogle Scholar

Dusetzina, S.B., Winn, A.N., Abel, G.A., Huskamp, H.A., and Keating, N.L., “Cost Sharing and Adherence to Tyro-sine Kinase Inhibitors for Patients with Chronic Myeloid Leukemia,” Journal of Clinical Oncology 32, no. 4 (2014): 306–311; Lopez-Valcarcel, B. Gonzalez et al., “Effect of Cost Sharing on Adherence to Evidence-Based Medications in Patients with Acute Coronary Syndrome,” Heart 103, no. 14 (2017): 1082–1088; Heidari, P., Cross, W., and Crawford, K., “Do Out-of-Pocket Costs Affect Medication Adherence in Adults with Rheumatoid Arthritis? A Systematic Review,” Seminars in Arthritis and Rheumatism 48, no. 1 (2018): 12–21; Karter, A.J. et al., “Effect of Out-of-Pocket Cost on Medication Initiation, Adherence, and Persistence among Patients with Type 2 Diabetes: The Diabetes Study of Northern California (DISTANCE),” Health Services Research 53, no. 2 (2018): 1227–1247.CrossRefGoogle Scholar

Dave, C.V., Kesselheim, A.S., Fox, E.R., Qiu, P., and Hartzema, A., “High Generic Drug Prices and Market Competition: A Retrospective Cohort Study,” Annals of Internal Medicine 167, no. 3 (2017): 145–151; Dave, C.V., Hartzema, A., and Kesselheim, A.S., “Prices of Generic Drugs Associated with Numbers of Manufacturers,” New England Journal of Medcine 377, no. 26 (2017): 2597–2598.Google Scholar

Gupta, R., Kesselheim, A.S., Downing, N., Greene, J., and Ross, J.S., “Generic Drug Approvals Since the 1984 Hatch-Waxman Act,” JAMA Internal Medicine 176, no. 9 (2016): 1391–1393.CrossRefGoogle Scholar

Grabowski, H., Long, G., Mortimer, R., and Boyo, A., “Updated Trends in US Brand-Name and Generic Drug Competition,” Journal of Medical Economics 19, no. 9 (2016): 836–844; Hemp-hill, C.S. and Sampat, B.N., “When Do Generics Challenge Drug Patents?” Journal of Empirical Legal Studies 8, no. 4 (2011): 613–649; Hemphill, C.S. and Sampat, B.N., “Evergreening, Patent Challenges, and Effective Market Life in Pharmaceuticals,” Journal of Health Economics 31, no. 2 (2012): 327–339.CrossRefGoogle Scholar

“Ultra Orphan Drugs,” The National Institute for Health and Care Excellence, 2004, available at <https://pubmed.ncbi.nlm.nih.gov/28230958/> (last visited October 22, 2020).+(last+visited+October+22,+2020).>Google Scholar

See Gupta et al, supra note 9.Google Scholar

Beall, R.F., Darrow, J.J., and Kesselheim, A.S., “A Method for Approximating Future Entry of Generic Drugs,” Value in Health 21, no. 12 (2018): 1382–1389.CrossRefGoogle Scholar

“FDA approves more generic drugs, but competition still lags: FY 2012-17 program achieves mixed results,” The PEW Charitable Trusts, February 25, 2019, available at <https://www.pewtrusts.org/en/research-and-analysis/issue-briefs/2019/02/fda-approves-more-generic-drugs-but-competition-still-lags> (last visited October 22, 2020).+(last+visited+October+22,+2020).>Google Scholar

Wiske, C.P., Ogbechie, O.A., and Schulman, K.A., “Options to Promote Competitive Generics Markets in the United States,” JAMA 314, no. 20 (2015): 2129–2130.CrossRefGoogle Scholar

Liljenquist, D., Bai, G., and Anderson, G.F., “Addressing Generic-Drug Market Failures — The Case for Establishing a Nonprofit Manufacturer,” New England Journal of Medicine 378, no. 20 (2018): 1857–1859.CrossRefGoogle Scholar

Kesselheim, A.S., Treasure, C.L., and Joffe, S., “Biomarker-Defined Subsets of Common Diseases: Policy and Economic Implications of Orphan Drug Act Coverage,” PLOS Medicine 14, no. 1 (2017): e1002190.Google Scholar